Go Pro
→ Barricks gold output fell from 2 million ounces to 719000 (From Golden Portfolio) (Ad)tc pixel Free BTCY Stock Alerts

Biotricity (BTCY) Competitors

Biotricity logo
$0.10 0.00 (-2.38%)
As of 03:56 PM Eastern
Compare

BTCY vs. MODD, ICCM, QNRX, HSCS, and FEMY

Should you buy Biotricity stock or one of its competitors? Biotricity's main competitors and comparable companies include Modular Medical (MODD), IceCure Medical (ICCM), Quoin Pharmaceuticals (QNRX), HeartSciences (HSCS), and Femasys (FEMY). Companies are selected based on similarities in market, industry, and size.

How does Biotricity compare to Modular Medical?

Biotricity (NASDAQ:BTCY) and Modular Medical (NASDAQ:MODD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

In the previous week, Modular Medical had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for Modular Medical and 0 mentions for Biotricity. Biotricity's average media sentiment score of 0.00 equaled Modular Medical'saverage media sentiment score.

Company Overall Sentiment
Biotricity Neutral
Modular Medical Neutral

3.9% of Biotricity shares are held by institutional investors. Comparatively, 27.5% of Modular Medical shares are held by institutional investors. 1.6% of Biotricity shares are held by insiders. Comparatively, 7.1% of Modular Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biotricity has higher revenue and earnings than Modular Medical. Biotricity is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biotricity$12.06M0.17-$14.09M-$0.12N/A
Modular MedicalN/AN/A-$28.24M-$14.71N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biotricity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Modular Medical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Biotricity has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Modular Medical has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Modular Medical has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Modular Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Biotricity-80.42% N/A -188.47%
Modular Medical N/A -286.34%-216.26%

Summary

Biotricity beats Modular Medical on 7 of the 12 factors compared between the two stocks.

How does Biotricity compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, IceCure Medical had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for IceCure Medical and 0 mentions for Biotricity. IceCure Medical's average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company Overall Sentiment
IceCure Medical Neutral
Biotricity Neutral

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 1.6% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Biotricity has higher revenue and earnings than IceCure Medical. Biotricity is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IceCure Medical$3.38M3.33-$15.06M-$7.21N/A
Biotricity$12.06M0.17-$14.09M-$0.12N/A

IceCure Medical has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

IceCure Medical currently has a consensus target price of $62.70, suggesting a potential upside of 1,811.59%. Given IceCure Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe IceCure Medical is more favorable than Biotricity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IceCure Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Biotricity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Biotricity has a net margin of -80.42% compared to IceCure Medical's net margin of -441.60%. Biotricity's return on equity of 0.00% beat IceCure Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
IceCure Medical-441.60% -211.73% -119.13%
Biotricity -80.42%N/A -188.47%

Summary

Biotricity beats IceCure Medical on 8 of the 15 factors compared between the two stocks.

How does Biotricity compare to Quoin Pharmaceuticals?

Biotricity (NASDAQ:BTCY) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Biotricity has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biotricity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Quoin Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Quoin Pharmaceuticals has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Biotricity-80.42% N/A -188.47%
Quoin Pharmaceuticals N/A -489.85%-221.29%

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for Quoin Pharmaceuticals and 0 mentions for Biotricity. Biotricity's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Biotricity Neutral
Quoin Pharmaceuticals Neutral

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 1.6% of Biotricity shares are owned by insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biotricity has higher revenue and earnings than Quoin Pharmaceuticals. Biotricity is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biotricity$12.06M0.17-$14.09M-$0.12N/A
Quoin PharmaceuticalsN/AN/A-$15.81M-$29.56N/A

Summary

Quoin Pharmaceuticals beats Biotricity on 7 of the 13 factors compared between the two stocks.

How does Biotricity compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

HeartSciences currently has a consensus target price of $8.00, indicating a potential upside of 286.47%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Biotricity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HeartSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Biotricity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 1.6% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, HeartSciences had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for HeartSciences and 0 mentions for Biotricity. HeartSciences' average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company Overall Sentiment
HeartSciences Neutral
Biotricity Neutral

HeartSciences has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat HeartSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
HeartSciencesN/A -358.60% -144.82%
Biotricity -80.42%N/A -188.47%

HeartSciences has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Biotricity has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

HeartSciences has higher earnings, but lower revenue than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeartSciencesN/AN/A-$9.14M-$3.94N/A
Biotricity$12.06M0.17-$14.09M-$0.12N/A

Summary

HeartSciences beats Biotricity on 10 of the 14 factors compared between the two stocks.

How does Biotricity compare to Femasys?

Biotricity (NASDAQ:BTCY) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Femasys has a consensus price target of $106.67, indicating a potential upside of 4,400.70%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Biotricity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biotricity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Femasys
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Biotricity has higher revenue and earnings than Femasys. Biotricity is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biotricity$12.06M0.17-$14.09M-$0.12N/A
Femasys$2.29M3.13-$18.63M-$5.40N/A

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 1.6% of Biotricity shares are owned by company insiders. Comparatively, 7.8% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Femasys had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for Femasys and 0 mentions for Biotricity. Femasys' average media sentiment score of 1.00 beat Biotricity's score of 0.00 indicating that Femasys is being referred to more favorably in the news media.

Company Overall Sentiment
Biotricity Neutral
Femasys Positive

Biotricity has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Femasys has a beta of -2.08, indicating that its stock price is 308% less volatile than the broader market.

Biotricity has a net margin of -80.42% compared to Femasys' net margin of -521.97%. Biotricity's return on equity of 0.00% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Biotricity-80.42% N/A -188.47%
Femasys -521.97%-258.08%-73.72%

Summary

Femasys beats Biotricity on 9 of the 16 factors compared between the two stocks.

Get Biotricity News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BTCY vs. The Competition

Export
MetricBiotricityHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.07M$5.82B$7.02B$12.98B
Dividend YieldN/A1.78%2.58%10.20%
P/E Ratio-0.0924.71269.1924.71
Price / Sales0.1761.03588.7697.69
Price / CashN/A33.5528.8937.42
Price / Book-0.086.2111.276.42
Net Income-$14.09M$147.87M$3.45B$347.03M
7 Day PerformanceN/A3.40%3.56%2.49%
1 Month Performance-21.09%1.66%-0.58%-1.04%
1 Year Performance-76.77%6.26%77.52%23.22%

Biotricity Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTCY
Biotricity
N/A$0.10
-2.4%		N/A-76.2%$2.07M$12.06MN/A40
MODD
Modular Medical
0.5192 of 5 stars		$2.07
-0.5%		N/A-90.2%$11.26MN/AN/A20
ICCM
IceCure Medical
2.6953 of 5 stars		$2.89
+0.3%		$62.70
+2,069.6%		-87.6%$9.87M$3.38MN/A60
QNRX
Quoin Pharmaceuticals
0.8339 of 5 stars		$4.40
+2.8%		N/A-32.6%$8.59MN/AN/A4
HSCS
HeartSciences
2.227 of 5 stars		$2.08
-3.7%		$8.00
+284.6%		-43.7%$8.42MN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BTCY) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
$8B is moving in... are you?
Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...
Awesomely | Sponsoredtc pixel
Real reason Trump banning Chinese models
President Trump's administration is drafting a ban on Chinese-made components used inside American AI data cen...
Porter & Company | Sponsoredtc pixel
A $5 stock inside Kennedy Space Center?
A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...
Freedom Financial | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
One trade you can make to move the needle today
Eric Fry has been analyzing markets since the 1980s, working as a professional portfolio manager for over a de...
InvestorPlace | Sponsoredtc pixel